Scheelevägen 19 A
98 articles with Alligator Bioscience
Alligator Bioscience announces that the scientific journal Expert Opinion on Biological Therapy has published an article by scientists at Alligator Bioscience, reviewing the field of CD40 agonistic antibodies.
Alligator Bioscience presents positive Phase I data at ASCO for its 4-1BB agonist drug candidate ATOR-1017
Alligator Bioscience presents novel supportive data from the ongoing Phase I clinical trial with the 4-1BB drug candidate ATOR-1017 developed as tumor-directed therapy for metastatic cancer.
Alligator Bioscience, announces that the annual general meeting was held in the company this day.
Alligator Bioscience announced that preclinical data on its agonist anti-CD40 antibody mitazalimab has been published in the scientific journal Cancer Immunology, Immunotherapy.
Alligator Bioscience announced that it has entered into a joint research agreement with BioArctic AB, a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.
So far, 2021 has been characterized by high activity, with a research collaboration that validates our Discovery concept, and good progress of our clinical programs, with ATOR-1017 and mitazalimab entering clinical efficacy studies this year.
The Nomination Committee's proposal regarding the board of directors ahead of the annual general meeting 2021 in Alligator Bioscience AB
Ahead of the annual general meeting in Alligator Bioscience AB on June 1, 2021 , the Nomination Committee announces its proposals regarding Chairman of the board, Vice Chairman of the board and other board members.
Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy
Alligator Bioscience announced that it has entered into a joint research collaboration with MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.
Alligator Bioscience announced that the board of directors has decided to postpone the Annual General Meeting to June 1, 2021, in connection with that Søren Bregenholt takes office as new CEO of Alligator.
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2020 has been published. The Annual Report is attached as a PDF and is available on the company's website, https://alligatorbioscience.se/en/investors/financial-reports/
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Board of Directors has appointed Søren Bregenholt, Ph.D. as the company's new Chief Executive Officer (CEO), to strengthen Alligator's business development activities and clinical progress on an international level.
Mitazalimab synergizes with chemotherapy - Alligator Bioscience presents new preclinical data at AACR
Alligator Bioscience announced that an abstract for a poster presentation at the AACR Annual Meeting 2021, presenting new preclinical data for the clinical asset mitazalimab, is now released.
Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with metastatic cancer.
Alligator Bioscience announced that the company has appointed Dr Christina Reimer as Chief Medical Officer.
Alligator Bioscience announced that it has submitted a CTA application to the relevant regulatory authorities to start a Phase II efficacy study of its wholly-owned CD40 targeting antibody mitazalimab.
Alligator Bioscience announced the completion of a novel proprietary human synthetic antibody library in Fab format - ALLIGATOR-FAB™.
Alligator Bioscience announced an approved IND for the CD40 targeting antibody mitazalimab. IND approval by the US Food and Drug Administration is a prerequisite to start clinical trials in the USA.
Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development
Alligator Bioscience ("Alligator") (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy and Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietar
Aptevo Therapeutics and Alligator Bioscience Advancing the Bispecific 4-1BBx5T4 Antibody ALG.APV-527 Into Phase 1 Clinical Development
Aptevo Therapeutics Inc. and Alligator Bioscience provided an update on ALG.APV-527, a novel immunotherapeutic bispecific candidate intended for the treatment of multiple solid tumors expressing 5T4, a tumor-restricted antigen.
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it will present data from three immuno-oncology projects at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting, November 9-14, 202